Connect with us

Business

AXIM Biotechnologies Inc. (OTCMKTS: AXIM) Partners WIthn Arizona State University To Develop A COVID-19 “Correlate of Portection”

Published

on

AXIM Biotechnologies Inc. (OTCMKTS: AXIM) has announced a partnership with Arizona State University (ASU)for the development of a COVID-19 “Correlate of protection” through the company’s rapid neutralizing antibody test.

AXIM and ASU collaborate to create a “Correlate of Protection” for COVID-19

The company and ASU will collaborate to meet this unmet need by determining a threshold for the decline of neutralizing antibodies to levels where they no longer prevent infection and disease. Neutralizing antibody levels will be utilized as a “Correlate of Protection” in this way.

ASU’s Dr. Douglas Lake will recruit a high-risk population and use AXIM’s quick neutralizing antibody test to monitor neutralizing antibody levels weekly, as well as PCR testing for the presence of SARS-CoV-2.

Dr. Lake said, “We expect that people whose neutralizing antibody levels are high will not become infected compared to those that have low levels of neutralizing antibodies. Using this study design, our goal is to develop a ‘Correlate of Protection’ so that people can keep their antibody levels high enough to avoid infection and potential transmission of the virus to vulnerable populations.”

AXIM Biotech CEO, John Huemoeller, added, “When our rapid test indicates that someone’s neutralizing antibody levels are low, healthcare providers might recommend a booster dose of COVID-19 vaccine, especially for someone who is high risk such as a healthcare provider, teacher, immunosuppressed or elderly. This study will answer the question on everyone’s mind, “How low do my neutralizing antibodies levels need to fall before I am no longer protected from COVID-19 infection?”

Measuring antiviral T-cells responses is challenging

Even though both T cells and antibodies play a role in COVID-19 protection, measuring antiviral T cell responses is logistically and technically challenging. Antiviral antibodies, unlike T cells, are reasonably easy to identify and quantify using a finger-stick drop of blood. The quick test from AXIM is unique in that it evaluates neutralizing antibodies levels, which protect against infection when blood levels are considerably high. The issue is that it is unknown at what levels of neutralizing antibodies infection is protected.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

FEATURED STORIES